Speaker
Description
Technological advances in molecular biology and biotechnology are increasingly used for the development of new tumor targeting tracers. In oncology, major progress has recently been achieved with peptidic and small molecule compounds. This relies on the identification and validation of new target structures in close conjunction with the application of new techniques for the development of new biocompatible molecules. These are based on either rational design or highthroughput methods. Their further evaluation and optimization consists in the characterization of the structure-function relationships and subsequent improvement with respect to binding, internalization and biodistribution of corresponding analogues. The concept will be shown for two the fibroblast activation protein ( FAP).
